Big pharmas Astellas Pharma and Daiichi Sankyo announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds.
The collaboration enables each party to promote innovative new medicine research and development.
This is the first time that a compound library partnership of this scale has been formed in Japan.
Astellas and Daiichi Sankyo have compound libraries that are the basis for their drug discovery research, and through High Throughput Screening (HTS)1), the companies can quickly and effectively search for potentially beneficial compounds to develop innovative new drugs.
Extensive, diverse, and high-quality compound libraries, such as the joint Astellas/Daiichi Sankyo libraries, are crucial to successful drug discovery.
This partnership will give each company access to qualitatively different compound librarieswhich have been developed based on the targeting disease strategies of each companyallowing both companies to implement broader HTS to generate innovative new drugs.
Astellas and Daiichi Sankyo will exchange approximately 400,000 selected compounds, including a significant number of proprietary synthetic compounds, from their respective compound libraries.
Beginning April 1, 2014, for a period of three years, both Astellas and Daiichi Sankyo will be able to implement broad HTS using the shared compounds without restrictions on targeted disease areas.
In line with the partnership, each company will disclose sufficient information to allow the receiving company to implement HTS independently.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Daiichi Sankyo
Report: Partnering Deals and Alliances with Astellas
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity